KCNA2 IgG autoimmunity in neuropsychiatric diseases

CONCLUSION: Our data suggest that KCNA2 autoimmunity is clinically heterogeneous. Future studies should determine whether KCNA2 autoantibodies are directly pathogenic or develop secondarily. Early immunotherapy should be considered, in particular if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical dementia, new-onset epilepsy and unexplained epileptic seizures.PMID:38309639 | DOI:10.1016/j.bbi.2024.01.220

Source: Brain, Behavior, and Immunity - February 3, 2024 Category: Neurology Authors: Friederike A Arlt Ramona Miske Marie-Luise Machule Peter Broegger Christensen Swantje Mindorf Bianca Teegen Kathrin Borowski Maria Buthut Rosa R ößling Elisa S ánchez-Sendín Scott van Hoof C ésar Cordero-Gómez Isabel B ünger Helena Radbruch Andrea Source Type: research